T1	intervention 75 109	tipifarnib combined with letrozole
T2	eligibility 393 504	Postmenopausal women with estrogen-receptor-positive advanced breast cancer that had progressed after tamoxifen
T3	control 606 613	placebo
T4	outcome-Measure 697 720	objective response rate
T5	total-participants 725 728	120
T6	intervention-participants 759 761	80
T7	control-participants 773 775	40
T8	total-participants 778 781	113
T9	outcome 811 834	Objective response rate
T10	iv-bin-percent 839 842	30%
T11	cv-bin-percent 871 874	38%
T12	outcome 998 1025	Clinical benefit rates were
T13	iv-bin-percent 1026 1029	49%
T14	cv-bin-percent 1039 1042	62%
T15	outcome 1111 1158	drug-related asymptomatic grade 3/4 neutropenia
T16	iv-bin-percent 1180 1183	18%
T17	cv-bin-percent 1197 1199	0%
T18	outcome 938 955	response duration
T19	outcome 957 984	time to disease progression
T20	outcome 988 996	survival
